Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Mol Cancer Ther. 2014 Feb 25;13(5):1105–1116. doi: 10.1158/1535-7163.MCT-13-0847

Figure 1.

Figure 1

ON123300 regulated MAPK and Akt pathways. [A] Chemical structure of ON123300. [B] U87 cells cultured on 10 cm plate were treated with 6.3 μM ON123300 for 1 h and cell lysates were analyzed by phospho-MAPK Array Kit (see Fig S1); Selected proteins shown above. ON123300 treatment decreased phosphorylated Akt, CREB and JNK pan expression levels. In contrast, p-Erk and p38γ were increased in cells treated with ON123300. [C] U87 cells cultured on 10 cm plate were treated with 6.3 μM ON123300, 70 μM ON1231120 or 10 μM ON1231320 for 1 h, and then cell homogenates were separated by SDS-PAGE gel and expression of p-Akt, phosphorylation levels of its downstream proteins and p-Erk were detected by western blotting. Total proteins and β-actin expression were used as control. ON123300 inhibited phosphorylation of Akt and its downstream signaling components, P70S6K, 40S ribosomal protein S6 [rpS6] and Rb S780 [decreased to 40.1% ± 5.7; 31.8 %± 2.1; 60.5% ± 1.0; 54.5% ± 6.3 relatively to control], yet increased p-Erk[increased to 120 % ± 6.9 relative to control]. The data shown are the measured mean values and S.D. of at least three experiments. *: p<0.05; **: p<0.01.